Euphorbia factor L3 is primarily studied for its potential antiviral properties, particularly against hepatitis B virus (HBV). It has demonstrated the ability to inhibit HBV surface antigen (HBsAg) secretion in cell-based assays, suggesting a role in suppressing viral expression. This compound is also investigated for its cytotoxic effects on certain cancer cell lines, showing promise as a lead compound in anticancer research. Due to its natural origin and unique structure, it serves as a candidate for developing novel therapeutic agents, especially in targeting viral infections and tumor growth. However, its application remains largely in the preclinical research stage, with ongoing studies to determine mechanism of action and potential for drug development.